Introduction
Chromoblastomycosis is one of the most frequently encountered mycoses in tropical and subtropical regions resulting from the implantation of the etiologic agent. It is characterized by slowly expanding skin lesions caused by a specifi c group of dematiaceous fungi [1, 2] . Several species have been reported as being involved in the disease etiology, including Cladophialophora carrionii [3],
Case report
A 55-year-old male farmer residing in Panyu district of Guangzhou, China, presented to our outpatient service on 25 August 2008 complaining of an ithy, erythematous plaque surrounded with verrucous hyperplasia on the medial of his right arm (Fig. 1a ). The lesion appeared and enlarged gradually after a localized trauma which occurred 13 years prior to his presentation. He had visited another hospital which resulted in a diagnosis of a deep mycosis, but for which he received no antifungal treatment. His family and past medical history was unremarkable and there was no evidence of any underlying diseases or that the patient was immunocompromised. Examination of potassium hydroxide mounts ( Fig. 2a ) and histopathology investigations revealed dematiaceous muriform cells ( Fig. 2b, 2c ) and based on these fi ndings, the patient was diagnosed as having chromoblastomycosis. Our mycological study and DNA sequencing indicated that the etiologic agent was F. monophora .
From 25 (Fig. 1b ). Due to these less than effective results, photodynamic therapy (PDT) employing 5-aminolevulinic acid (ALA) irradiation was initiated. The patient received ALA-PDT irradiation by itself 5 times, at weekly intervals from 22 April 2010 to 20 May 2010 ( Fig.  1c ). Then ALA-PDT irradiation was combined with terbinafi ne, 250mg/day per os, 5 times, again at weekly intervals from 9 September 2010 to 28 October 2010. In between the irradiation treatments, terbinafi ne 250 mg/day per os was employed. Although the lesions were obviously clinically improved, microscopic examinations revealed the presence of fungi ( Fig. 1d ) and new lesions developed after the withdrawal of ALA-PDT (Fig. 1e ). The therapy was changed after 2 December 2010 to voriconazole 200 mg/day combined with terbinafi ne 250 mg/day per os. Two months later, clinical improvement could be observed ( Fig. 1f ) but since mycological examination was still positive, the patient is now under follow-up in the outpatient clinical.
Identifi cation of isolates

Mycological investigation
A microscopic examination of scales from the lesion in KOH revealed the presence of muriform cells (dark brown large cells; Fig. 2a ). Histopathology studies of a portion of a biopsy specimen demonstrated the presence of mild acanthosis of the epidermis, granulomatous infl ammation around the entire dermis and muriform cells in microabscesses or giant cells ( Fig. 2b, 2c ).
DNA sequence analyses
DNA was extracted using 6% InStaGene Matrix (BioRad, Hercules, CA, USA). Ribosomal DNA ITS domains were Standards Institute (CLSI) guidelines (M38-A document) as previously described [13] . Itraconazole (Xian-Janssen Pharmaceutical Ltd, Xi ' an, China), terbinafi ne (Beijing Novartis Pharmaceutical Ltd. [Beijing, China] ) and voriconazole (Sigma, USA) were dissolved in 100% DMSO to prepare stock solutions (3,200 μ g/ml). The drugs were then diluted to obtain the fi nal concentrations, which for itraconazole and voriconazole were from 0.008 -8 μ g/ml and terbinafi ne concentrations of from 0.008 -0.5 μ g/ml. The isolates were subcultured and the supernatant of the colonies were collected and adjusted with saline to achieve an inoculum concentration of 10 6 conidia/ml. Each suspension was diluted 1:50 -100 with RPMI 1640 to obtain the fi nal test inoculum (0.4 -5 ϫ 10 4 conidia/ml). Suspensions of conidia of each the tested strains were inoculated into RPMI 1640 medium and incubated for 7 days at 35 ° C. Candida parapsilosis ATCC22019, obtained from Centraalbureau voor Schimmelcultures (CBS, The Netherlands), was used as a quality control. The fi nal test amplifi ed in a Biometra T-Gradient Thermoblock (Whatman Biometra, Goettingen, Germany) using primers ITS-5 (5 ¢ -GGAAGTAAAAGTCGTAACAAGG-3 ¢ ) and ITS-4 (5 ¢ -TCCTCCGCTTATTGATATGC-3 ¢ ). PCR was carried out at 94 ° C for 5 min, followed by 30 cycles at 94 ° C for 60 s, annealing at 55 ° C for 90 s and an extension at 72 ° C for 90 s. The reaction continued at 72 ° C for 10 min. The DNA fragments were sequenced with an ABI PRISM 3100 sequencer (Applied Biosystems, Foster City, CA, USA). The sequence showed 99% homology with type strain SUMS 0246 in GenBank (EF 513768.1) and was confi rmed as F. monophora . The sequences data of the isolates was deposited in the GenBank with accession number JN629041.
Antifungal susceptibility testing
The in vitro antifungal susceptibility of the clinical isolate was assessed in accord with the Clinical Laboratory and inoculum concentration was 0.5 -2.5 ϫ 10 3 conidia/ml. The results of the susceptibility testing are shown in Table 1 .
Discussion
F. monophora , presently recognized as one of the agents of human chromoblastomycosis, was fi rst described by De Hoog [5] . Our patient had a history of trauma and had lesions on exposed area of his body. Muriform cells were observed in microscopic examinations of smears and histopathology studies of biopsy materials. The identifi cation of the suspected etiologic agent as F. monophora leads to the diagnosis of chromoblastomycosis. Various antifungals have been used in treating this infection, with the best clinical outcomes obtained with itraconazole and terbinafi ne among the oral and systemically used drugs [11] . In the present case, the patient was initially treated with terbinafi ne or itraconazole or the combination of the two but without any response. Topical PDT, which combines a non-toxic dye, termed a photosensitizer (PS), with low intensity harmless visible light to generate reactive oxygen species that are toxic to selected cells, was fi rst applied in the fi eld of oncology [15] . It has become a well-established treatment in dermatology for the prevention and treatment of a variety of malignant skin tumors and infl ammatory diseases, including non-melanoma skin cancer, actinic keratoses, acne vulgaris, photorejuvenation, and hidradenitis suppurativa [16] . Moreover, the use of PDT has been extended to antimicrobial chemotherapy, including its application in fungal infections with no reports of resistance of the etiologic agents [17] . Recently there was a description of promising results being obtained through the use of PDT (employing methylene blue as photosensitizer) in the treatment of chromoblastomycosis 18]. In the present case, PDT treatment did greatly reduce the size of the patient ' s lesions, despite the fact that complete mycologic or clinical cure was not obtained. These results demonstrate that ALA was metabolized into protoporphyrin IX (PpIX) and targeted to the etiologic agent. The result of in vitro studies is compatible with clinical response, which showed growth inhibiting effect of ALA/ PDT on F. monophora (unpublished data).
Voriconazole has a broader spectrum of activity and an increased biochemical affi nity to fungal 14a-demethylase, resulting in its strong antifungal activity [19] . In addition, clinical isolates of Fonsecaea spp. have been found through in vitro studies to be highly sensitive to the drug [20] . Despite the high cost, voriconazole is a safe and promising antifungal for use in treating extensive chromoblastomycosis that is refractory to the conventional therapeutic regimens. The result of the present study confi rms earlier reports that voriconazole provides an effective therapy of chromoblastomycosis caused by Fonsecaea [12] .
Our isolate of F. monophora was found by in vitro antifungal susceptibility studies to be sensitive to terbinafi ne, itraconazole, voriconazole, with MICs of 0.125, 1 and 0.0625 μ g/ml, respectively. These results suggest that while in vitro susceptibility profi les may be useful to indentify intrinsic microbiologic resistance to antifungal drugs, they do not predict clinical responses [21] . It must be remembered that the patient status and the lesions caused by the infection are important factors in determining the effects of treatment. Our previous study demonstrated a synergistic effect created by terbinafi ne and itraconazole on clinical isolates of F. monophora [22, 23] . Voriconazole, the second generation of triazole, has a similar structure to itraconazole and its use with terbinafi ne may also be synergistic. Further studies are necessary to confi rm the results.
Although chromoblastomycosis is associated with low cure and high relapse rates [4], most cases caused by F. monophora have been successfully treated. This is the fi rst refractory case described in China. Independent to the MIC of the etiologic agent, the poor response to treatment may due to the development of fi brosis which did not allow the antimycotics to penetrate. Although complete cure was not achieved, voriconazole and PDT are promising methods in the treatment of chromoblastomycosis. 
